Jason Hannon to serve as new Mainstay Medical CEO: 5 highlights

Written by Megan Wood | September 05, 2017 | Print  |

Jason Hannon will take the helm of Mainstay Medical Oct. 9, according to MarketsInsider.

Here are five highlights:


1. Mr. Hannon will replace current CEO Peter Crosby, who is retiring. Mr. Crosby will serve as a consultant to the company until the end of 2020.


2. Mr. Hannon will also serve as a director, effective Oct. 9.


3. With a 12-year career at NuVasive, Mr. Hannon served as the company's president and COO.


4. Mainstay Medical develops ReActiv8, an implantable restorative neurostimulation system.


5. The company is conducting the ReActiv8 clinical trial to gather data for its FDA pre-market approval application.


More articles on devices:
Medtronic to study Infuse in PLF, TLIF spine surgeries in new pilot trials: 5 things to know
Medtronic, NuVasive, InVivo Therapeutics & more: 6 device company notes
Stryker completes Novadaq Technologies acquisition: 3 insights

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies here.

Featured Webinars

Featured Whitepapers